-
公开(公告)号：US10085986B2
公开(公告)日：2018-10-02
申请号：US14131337
申请日：2012-07-05
Applicant: Xiao-Ling Fan Cockcroft , William Farnaby , Natasha Kinsella , Kevin Merchant , David Miller
Inventor： Xiao-Ling Fan Cockcroft , William Farnaby , Natasha Kinsella , Kevin Merchant , David Miller
IPC: C07F9/02 , A61K31/513 , C07D239/54 , C07D239/60 , A61K45/06 , C07D239/22 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D471/04
Abstract: The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
-
2.发明授权5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain 有权5-或6-取代的3-羟基-2（1H） - 吡啶酮作为D-氨基酸氧化酶（DAAO）抑制剂治疗精神分裂症，认知障碍和疼痛等疾病公开(公告)号：US09180122B2
公开(公告)日：2015-11-10
申请号：US14131343
申请日：2012-07-05
Applicant: William Farnaby , Charlotte Fieldhouse , Catrina Kerr , Natasha Kinsella , David Livermore , Kevin Merchant , David Miller , Katherine Hazel
Inventor： William Farnaby , Charlotte Fieldhouse , Catrina Kerr , Natasha Kinsella , David Livermore , Kevin Merchant , David Miller , Katherine Hazel
IPC: A61K31/4412 , A61K31/444 , A61K31/497 , A61K45/06 , C07D213/69 , C07D213/70 , C07D213/71 , C07D401/12 , C07D413/12
CPC classification number: A61K31/4412 , A61K31/444 , A61K31/497 , A61K45/06 , C07D213/69 , C07D213/70 , C07D213/71 , C07D401/12 , C07D413/12
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or fluorine, one of A and B is R2, the other is a group —X—Y—R3. R3 represents a carbocyclic or heterocyclic ring. Further variables are as defined in the specification. Also claimed are—processes for their preparation, pharmaceutical compositions containing them and their use in therapy of diseases such as schizophrenia, cognitive disorders and pain by modulating the D-amino acid oxidase enzyme (DAAO).
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，其中R 1是氢或氟，A和B之一是R 2，另一个是-X-Y-R 3基团。 R3表示碳环或杂环。 其他变量如本说明书中所定义。 还要求保护其制备方法，含有它们的药物组合物及其在治疗疾病如精神分裂症，认知障碍和通过调节D-氨基酸氧化酶（DAAO）的疼痛中的用途）。
-
公开(公告)号：US20070281952A1
公开(公告)日：2007-12-06
申请号：US11791195
申请日：2005-11-28
Applicant: Mark Chambers , Neil Curtis , Emanuela Gancia , Myra Gilligan , Alexander Humphries , Tamara Ladduwahetty , Robert Maxey , Kevin Merchant
Inventor： Mark Chambers , Neil Curtis , Emanuela Gancia , Myra Gilligan , Alexander Humphries , Tamara Ladduwahetty , Robert Maxey , Kevin Merchant
IPC: A61K31/495 , A61K31/41 , A61K31/415 , A61K31/52 , A61P25/20 , A61P25/24 , A61P27/06 , C07D213/02 , C07D231/10 , C07D473/00 , C07D239/02 , C07D233/00 , C07D221/02 , C07C317/00 , A61P25/30 , A61P25/22 , A61P25/18 , A61K31/435 , A61K31/4353
CPC classification number: C07D401/12 , C07C311/08 , C07C317/14 , C07C317/22 , C07C317/24 , C07C317/32 , C07C317/42 , C07C317/44 , C07C323/65 , C07C2601/04 , C07D213/61 , C07D213/64 , C07D213/70 , C07D215/36 , C07D215/60 , C07D233/64 , C07D241/12 , C07D249/06 , C07D249/08 , C07D249/18 , C07D261/08 , C07D271/10 , C07D277/26 , C07D333/34 , C07D471/04 , C07D473/38
Abstract: Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.
Abstract translation: 式（I）化合物是有效和选择性的5-HT 2AA拮抗剂，可用于治疗CNS的多种不利条件。
-
公开(公告)号：US20060189666A1
公开(公告)日：2006-08-24
申请号：US10566486
申请日：2004-07-29
Applicant: Michela Bettati , Amanda Boase , Ian Churcher , Tamara Ladduwahetty , Kevin Merchant , Abdul Quddus
Inventor： Michela Bettati , Amanda Boase , Ian Churcher , Tamara Ladduwahetty , Kevin Merchant , Abdul Quddus
IPC: A61K31/433 , C07D498/12
CPC classification number: C07D231/12 , C07D417/06
Abstract: Compounds of Formula (I): inhibit the processing of APP by gamma-secretase, and hence are useful for treatment or prevention of Alzheimer's disease.
Abstract translation: 式（I）的化合物：通过γ-分泌酶抑制APP的加工，因此可用于治疗或预防阿尔茨海默氏病。
-
公开(公告)号：US20090012134A1
公开(公告)日：2009-01-08
申请号：US11885925
申请日：2006-03-10
Applicant: Neil Roy Curtis , Emanuela Garcia , Tamara Ladduwahetty , Robert Maxey , Kevin Merchant , Andrew Mitchinson
Inventor： Neil Roy Curtis , Emanuela Garcia , Tamara Ladduwahetty , Robert Maxey , Kevin Merchant , Andrew Mitchinson
IPC: A61K31/428 , C07D209/04 , C07D277/62 , A61K31/404 , A61K31/4184 , C07D235/04
CPC classification number: C07D307/79 , C07D209/08 , C07D209/10 , C07D209/42 , C07D231/56 , C07D277/66 , C07D333/54
Abstract: Compounds of formula (I): are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders.
Abstract translation: 式（I）化合物是5-HT 2A受体的有效和选择性拮抗剂，因此可用于治疗各种CNS疾病。
-
Patent Agency Ranking
公开(公告)号：US20070203205A1
公开(公告)日：2007-08-30
申请号：US11796389
申请日：2007-04-27
Applicant: Jose Castro Pineiro , Laura Cooper , Myra Gilligan , Alexander Humphries , Peter Hunt , Tamara Ladduwahetty , Angus MacLeod , Kevin Merchant , Monique Van Niel , Kevin Wilson
Inventor： Jose Castro Pineiro , Laura Cooper , Myra Gilligan , Alexander Humphries , Peter Hunt , Tamara Ladduwahetty , Angus MacLeod , Kevin Merchant , Monique Van Niel , Kevin Wilson
IPC: A61K31/4245 , A61K31/4164 , A61K31/235 , A61K31/10
CPC classification number: C07C317/28 , C07C317/14 , C07C317/22 , C07C317/24 , C07C317/32 , C07C317/36 , C07C317/42 , C07C317/44 , C07D205/04 , C07D207/10 , C07D211/38 , C07D211/72 , C07D213/34 , C07D213/71 , C07D217/24 , C07D231/12 , C07D233/64 , C07D241/08 , C07D249/08 , C07D261/08 , C07D271/10 , C07D277/26 , C07D295/096 , C07D317/62 , C07D319/18
Abstract: Compounds of formula I: are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
-
公开(公告)号：US09290456B2
公开(公告)日：2016-03-22
申请号：US14240045
申请日：2012-08-21
Applicant: William Farnaby , Charlotte Fieldhouse , Katherine Hazel , Catrina Kerr , Natasha Kinsella , David Livermore , Kevin Merchant , David Miller
Inventor： William Farnaby , Charlotte Fieldhouse , Katherine Hazel , Catrina Kerr , Natasha Kinsella , David Livermore , Kevin Merchant , David Miller
IPC: C07D237/16 , C07D401/06 , A61K31/50 , A61K31/501 , C07D401/10 , C07D407/10 , A61K45/06 , C07D237/18 , C07D237/22 , C07D405/06 , C07F7/08
CPC classification number: A61K31/50 , A61K31/501 , A61K45/06 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/06 , C07D401/10 , C07D405/06 , C07D407/10 , C07F7/0812
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，其中R1和R2如说明书中所定义，其制备方法，含有它们的药物组合物及其在治疗中的用途。
-
公开(公告)号：US20150030704A1
公开(公告)日：2015-01-29
申请号：US14240045
申请日：2012-08-21
Applicant: William Farnaby , Charlotte Fieldhouse , Katherine Hazel , Catrina Kerr , Natasha Kinsella , David Livermore , Kevin Merchant , David Miller
Inventor： William Farnaby , Charlotte Fieldhouse , Katherine Hazel , Catrina Kerr , Natasha Kinsella , David Livermore , Kevin Merchant , David Miller
IPC: C07D237/16 , C07D401/06 , A61K45/06 , C07D237/18 , C07D237/22 , C07D405/06 , A61K31/50 , A61K31/501
CPC classification number: A61K31/50 , A61K31/501 , A61K45/06 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/06 , C07D401/10 , C07D405/06 , C07D407/10 , C07F7/0812
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，其中R1和R2如说明书中所定义，其制备方法，含有它们的药物组合物及其在治疗中的用途。
-
公开(公告)号：US20140248378A1
公开(公告)日：2014-09-04
申请号：US14131337
申请日：2012-07-05
Applicant: Xiao-Ling Fan Cockcroft , William Farnaby , Natasha Kinsella , Kevin Merchant , David Miller
Inventor： Xiao-Ling Fan Cockcroft , William Farnaby , Natasha Kinsella , Kevin Merchant , David Miller
IPC: A61K31/513 , C07D239/22 , C07D403/12 , C07D401/12 , A61K45/06 , C07D471/04 , C07D413/12 , C07D405/12
CPC classification number: A61K31/513 , A61K45/06 , C07D239/22 , C07D239/54 , C07D239/60 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D471/04
Abstract: The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, Y and Z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract translation: 本发明提供式（1）化合物及其药学上可接受的盐，其中R1，R2，Y和Z如说明书中所定义，其制备方法，含有它们的药物组合物及其在治疗中的用途。
-
公开(公告)号：US20130052281A1
公开(公告)日：2013-02-28
申请号：US13591859
申请日：2012-08-22
Applicant: William FARNABY , Charlotte FIELDHOUSE , Catrina KERR , Natasha KINSELLA , David LIVERMORE , Kevin MERCHANT , David MILLER , Katherine HAZEL
Inventor： William FARNABY , Charlotte FIELDHOUSE , Catrina KERR , Natasha KINSELLA , David LIVERMORE , Kevin MERCHANT , David MILLER , Katherine HAZEL
IPC: C07D237/16 , C07D401/06 , C07D237/18 , A61K31/50 , A61K31/501 , C07D405/06 , C07D237/22 , A61K31/55 , A61K31/5513 , A61K31/554 , A61K31/53 , A61K31/519 , A61K33/00 , A61P25/18 , A61P25/00 , A61P29/00 , C07F7/10
CPC classification number: A61K31/50 , A61K31/501 , A61K45/06 , C07D237/16 , C07D237/18 , C07D237/22 , C07D401/06 , C07D401/10 , C07D405/06 , C07D407/10 , C07F7/0812
Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，其中R1和R2如说明书中所定义，其制备方法，含有它们的药物组合物及其在治疗中的用途。
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.021 seconds)
